Articles of the Month
Videos
Articles
Reducing the risks of nuclear war—the role of health professionals
Abbasi, K., Ali, P., Barbour, V., et al. Allergy. First published: 21 August 2023
Commercial shellfish skin prick test extracts show critical variability in allergen repertoire
Ruethers, T., Johnston, E.B., Karnaneedi, S., et al. Allergy. First published: 21 August 2023
Efficacy and safety of on-demand versus daily rupatadine in chronic spontaneous urticaria: A randomized trial
Weller, K, Gimenez-Arnau, AM, Baron, J, et al. Allergy. First published: 19 August 2023
An EAACI review: Go green in health care and research. Practical suggestions for sustainability in clinical practice, laboratories, and scientific meetings
Pali-Schöll, I, Hermuth-Kleinschmidt, K, Dramburg, S, et al. Allergy. First published: 16 August 2023
Current state and prospects of artificial intelligence in allergy
van Breugel, M, Fehrmann, RSN, Bügel, M, et al. Allergy. First published: 16 August 2023
Intrapatient comparison of atopic dermatitis skin transcriptome shows differences between tape-strips and biopsies
Del Duca, E, He, H, Liu, Y, et al. Allergy. First published: 14 August 2023
Epigenetic responses to rhinovirus exposure in airway epithelial cells are correlated with key transcriptional pathways in chronic rhinosinusitis
Soliai, MM, Kato, A, Naughton, KA, et al. Allergy. First published: 12 August 2023
β-1,3-glucan, but not β-1,3/1,6-glucan, exacerbates experimental food allergy, while both increase IgA induction
He, C., Liu, Y., Schülke, S., et al. Allergy. First published: 11 August 2023
MASK-air® direct patient data support the ARIA-MeDALL hypothesis on allergic phenotypes
Bousquet, J., Sousa-Pinto, B., Regateiro, F.S., et al. Allergy. First published: 11 August 2023
Annexin A5 inhibits mast cell activation via Allergin-1 immunoreceptor
Almeida, M.S., Tahara-Hanaoka, S., Shibagaki, S., et al. Allergy. First published: 11 August 2023
A machine learning approach for stratifying risk for food allergies utilizing electronic medical record data
Landau, T., Gamrasni, K., Barlev, Y., et al. Allergy. First published: 09 August 2023
Autoreactive IgE: Pathogenic role and therapeutic target in autoimmune diseases
Charles, N, Kortekaas-Krohn, I, Kocaturk, E, et al. Allergy. First published: 09 August 2023
Interferon-γ-inducible protein 10 augments atopic dermatitis via amplifying Th2 immune response
Choi, Y.-A., Kim, N., Jeong, N.-H., et al. Allergy. First published: 07 August 2023
Oral immunotherapy in alpha-gal red meat allergy: Could specific IgE be a potential biomarker in monitoring management?
Ünal, D, Eyice-Karabacak, D, Kutlu, A, et al. Allergy. First published: 07 August 2023
Dupilumab-induced eosinophilia in patients with diffuse type 2 chronic rhinosinusitis
Ryser, FS, Yalamanoglu, A, Valaperti, A, et al. Allergy. First published: 07 August 2023
Eosinophilic allergic rhinitis is strongly associated with the CD45RBlo subset of CD161+ Th2 cells that secretes IL-2, IL-3, IL-4, IL-5, IL-9, and IL-13
Lee, W.W.L., Puan, K.J., Lee, B., et al. Allergy. First published: 07 August 2023
Meglumine gadoterate induces immunoglobulin-independent human mast cell activation via MRGPRX2
Ruiz de Azcárate, P.H., López-Sanz, C., López-Raigada, A., et al. Allergy. First published: 07 August 2023
How does allergen immunotherapy-induced tolerance improve the airway epithelial barrier function: A mechanistical-driven hypothesis
Pfaar, O., Fritzsching, B., Wolf, H., et al. Allergy. First published: 06 August 2023
Topical corticosteroids inhibit allergic skin inflammation but are ineffective in impeding the formation and expansion of resident memory T cells
Ono, E, Lenief, V, Lefevre, M-A, et al. Allergy. First published: 04 August 2023
A comparison of double-blind, placebo-controlled food challenge and open food challenge
Jessen, FB, Mortz, CG, Eller, E, et al. Allergy. First published: 04 August 2023
Rural and urban exposures shape early life immune development in South African children with atopic dermatitis and nonallergic children
Lunjani, N, Ambikan, AT, Hlela, C, et al. Allergy. First published: 03 August 2023
Mechanisms of gut epithelial barrier impairment caused by food emulsifiers polysorbate 20 and polysorbate 80
Ogulur, I, Yazici, D, Pat, Y, et al. Allergy. First published: 02 August 2023
Patients with naproxen-induced liver injury display T-cell memory responses toward an oxidative (S)-O-Desmethyl Naproxen metabolite but not the acyl glucuronide
Thomson, P, Fragkas, N, Kafu, LM, et al. Allergy. First published: 29 July 2023
Immunoglobulin G4 in eosinophilic esophagitis: Immune complex formation and correlation with disease activity
Medernach, JG, Li, R-C, Zhao, X-Y, et al. Allergy. First published: 27 July 2023
Reply to correspondence to ‘Diagnosis of immediate reactions to amoxicillin: Comparison of basophil activation markers CD63 and CD203c in a prospective study’
Fernández, T.D., Mayorga, C. and Torres, M.J. Allergy. First published: 27 July 2023
Different mechanisms distinguishing childhood allergic diseases including allergic march
Oh, H.Y., Kim, J.-H., Yeom, J., et al. Allergy. First published: 27 July 2023
Real-life evaluation of tolerance to foods with precautionary allergen labeling in children with IgE-mediated food allergy
Graham, F., Benhamou, A.H., Liu, Y.J., Caubet, J.-C. and Eigenmann, P.A. Allergy. First published: 26 July 2023
Complementary feeding practices are related to the risk of food allergy in the ELFE cohort
Adam, T, Divaret-Chauveau, A, Roduit, C, et al. Allergy. First published: 26 July 2023
Immunoglobulin E autoantibodies in atopic dermatitis associate with Type-2 comorbidities and the atopic march
Kortekaas Krohn, I, Badloe, FMS, Herrmann, N, et al. Allergy. First published: 24 July 2023
Identification of extracellular vesicle microRNA signatures specifically linked to inflammatory and metabolic mechanisms in obesity-associated low type-2 asthma
Alhamdan, F, Greulich, T, Daviaud, C, et al. Allergy. First published: 24 July 2023
The association between allergic rhinitis and the risk of coronavirus disease 2019 (COVID-19): A national survey in China
Yang, X., Zhao, J., Sima, Y., et al. Allergy. First published: 21 July 2023
Large cohort study shows increased risk of developing atopic dermatitis after COVID-19 disease
Schmitt, J., Ehm, F., Vivirito, A., et al. Allergy. First published: 20 July 2023
Mind and skin: Exploring the links between inflammation, sleep disturbance and neurocognitive function in patients with atopic dermatitis
Cameron, S, Donnelly, A, Broderick, C, et al. Allergy. First published: 19 July 2023
Improved ambient air quality is associated with decreased prevalence of childhood asthma and infancy shortly after weaning is a sensitive exposure window
Chen, T, Shi, S, Li, X, et al. Allergy. First published: 17 July 2023
Allergic bronchopulmonary aspergillosis with atopic, nonatopic, and sans asthma—Factor analysis
Okada, N, Yamamoto, Y, Oguma, T, et al. Allergy. First published: 17 July 2023
Tralokinumab therapy for moderate-to-severe atopic dermatitis: Clinical outcomes with targeted IL-13 inhibition
Simpson, EL, Guttman-Yassky, E, Eichenfield, LF, et al. Allergy. First published: 16 July 2023
Citations: 138
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria
Zuberbier, T, Abdul Latiff, AH, Abuzakouk, M, Aquilina, S, Asero, R, Baker, D, et al. Allergy. 2022; 77: 734– 766
Citations: 98
The role of peripheral blood eosinophil counts in COVID-19 patients
Xie, G, Ding, F, Han, L, Yin, D, Lu, H, Zhang, M. Allergy. 2021; 76: 471– 482
Citations: 70
EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines
Sokolowska, M., Eiwegger, T., Ollert, M., Torres, M.J., Barber, D., Del Giacco, S., et al. Allergy. 2021; 76: 1629-1639
Citations: 68
COVID-19 pandemic: Practical considerations on the organization of an allergy clinic—An EAACI/ARIA Position Paper
Pfaar, O, Klimek, L, Jutel, M, Akdis, C, A, Bousquet, J, Breiteneder, H, et al. Allergy. 2021; 76: 648– 676
Citations: 65
ARIA-EAACI statement on severe allergic reactions to COVID-19 vaccines – An EAACI-ARIA Position Paper
Klimek, L., Jutel, M., Akdis, C.A., Bousquet, J., Akdis, M., Torres, M.J., et al. Allergy. 2021; 76: 1624-1628
Citations: 61
Allergic reactions to the first COVID-19 vaccine: A potential role of polyethylene glycol?
Cabanillas, B., Akdis, C.A. and Novak, N. Allergy. 2021; 76: 1617-1618
Citations: 58
Allergenic components of the mRNA-1273 vaccine for COVID-19: Possible involvement of polyethylene glycol and IgG-mediated complement activation
Klimek, L., Novak, N., Cabanillas, B., Jutel, M., Bousquet, J. and Akdis, C.A. Allergy. 2021; 76: 3307-3313
Citations: 55
Vaccines and allergic reactions: The past, the current COVID-19 pandemic, and future perspectives
Sampath, V., Rabinowitz, G., Shah, M., Jain, S., Diamant, Z., Jesenak, M., et al. Allergy. 2021; 76: 1640-1660
Citations: 49
EAACI guidelines: Anaphylaxis (2021 update)
Muraro, A, Worm, M, Alviani, C, Cardona, V, DunnGalvin, A, Garvey, L, H, et al et al. Allergy. 2022; 2022; 77: 357– 377
Citations: 43
The role of allergen-specific IgE, IgG and IgA in allergic disease
Shamji, MH, Valenta, R, Jardetzky, T, Verhasselt, V, Durham, S, R, Würtzen, P, A, et al. Allergy. 2021; 76: 3627– 3641
Citations: 43
Childhood asthma outcomes during the COVID-19 pandemic: Findings from the PeARL multi-national cohort
Papadopoulos, N.G., Mathioudakis, A.G., Custovic, A., Deschildre, A., Phipatanakul, W., Wong, G., et al. Allergy. 2021; 76: 1765-1775
Citations: 43
Basophil activation test: Mechanisms and considerations for use in clinical trials and clinical practice
Santos, A.F., Alpan, O. and Hoffmann, H.-J. Allergy. 2021; 76: 2420-2432
Citations: 42
Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines
Agache, I., Song, Y., Alonso-Coello, P., Vogel, Y., Rocha, C., Solà, I., et al. Allergy. 2021; 76: 2337-2353
Citations: 39
In vitro data suggest that Indian delta variant B.1.617 of SARS-CoV-2 escapes neutralization by both receptor affinity and immune evasion
Augusto, G, Mohsen, MO, Zinkhan, S, Liu, X, Vogel, M, Bachmann, MF. Allergy. 2022; 77: 111– 117
Citations: 38
Anaphylaxis to the first dose of mRNA SARS-CoV-2 vaccines: Don't give up on the second dose!
Krantz, M.S., Bruusgaard-Mouritsen, M.A., Koo, G., Phillips, E.J., Stone, C.A., Jr and Garvey, L.H. Allergy. 2021; 76: 2916-2920
Citations: 37
Elastase and exacerbation of neutrophil innate immunity are involved in multi-visceral manifestations of COVID-19
Guéant, J.-L., Guéant-Rodriguez, R.-M., Fromonot, J., Oussalah, A., Louis, H., Chery, C., et al. Allergy. 2021; 76: 1846-1858
Citations: 35
Profound dysregulation of T cell homeostasis and function in patients with severe COVID-19
Adamo, S., Chevrier, S., Cervia, C., Zurbuchen, Y., Raeber, M.E., Yang, L., et al. Allergy. 2021; 76: 2866-2881
Citations: 34
Practice parameters for diagnosing and managing iodinated contrast media hypersensitivity
Torres, MJ, Trautmann, A, Böhm, I, Scherer, K, Barbaud, A, Bavbek, S, et al. Allergy. 2021; 76: 1325– 1339
Citations: 34
The ingenious mast cell: Contemporary insights into mast cell behavior and function
Dahlin, J.S., Maurer, M., Metcalfe, D.D., Pejler, G., Sagi-Eisenberg, R. and Nilsson, G. Allergy. 2022; 77: 83-99
Citations: 34
Silencing of SARS-CoV-2 with modified siRNA-peptide dendrimer formulation
Khaitov, M., Nikonova, A., Shilovskiy, I., Kozhikhova, K., Kofiadi, I., Vishnyakova, L., et al. Allergy. 2021; 76: 2840-2854
Citations: 34
Interleukin-31: The “itchy” cytokine in inflammation and therapy
Datsi, A., Steinhoff, M., Ahmad, F., Alam, M. and Buddenkotte, J. Allergy. 2021; 76: 2982-2997
Citations: 32
Predictors of treatment response in chronic spontaneous urticaria
Fok, J.S., Kolkhir, P., Church, M.K. and Maurer, M. Allergy. 2021; 76: 2965-2981
Citations: 31
Skin tests in urticaria/angioedema and flushing to Pfizer-BioNTech SARS-CoV-2 vaccine: Limits of intradermal testing
Bianchi, L., Biondi, F., Hansel, K., Murgia, N., Tramontana, M. and Stingeni, L. Allergy. 2021; 76: 2605-2607
Citations: 31
Current perspective on eicosanoids in asthma and allergic diseases: EAACI Task Force consensus report, part I
Sokolowska, M, Rovati, GE, Diamant, Z, et al. Allergy. 2021; 76: 114– 130
Citations: 30
Epithelial barrier hypothesis: Effect of the external exposome on the microbiome and epithelial barriers in allergic disease
Celebi Sozener, Z, Ozdel Ozturk, B, Cerci, P, et al. Allergy. 2022; 77: 1418– 1449
Citations: 30
Advances and highlights in asthma in 2021
Agache, I, Eguiluz-Gracia, I, Cojanu, C, et al. Allergy. 2021; 76: 3390– 3407
February 2023 - Food Allergy and Allergic/Inflammatory Gastrointestinal Diseases
Volume 78 | Issue 2
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria
Zuberbier, T, Abdul Latiff, AH, Abuzakouk, M, et al. Allergy. 2022; 77: 734– 766
The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
Zuberbier, T., Aberer, W., Asero, R., Abdul Latiff, A., H., Baker, D., Ballmer-Weber, B. et al. Allergy. 2018; 73: 1393- 1414
Risk factors for severe and critically ill COVID-19 patients: A review
Gao, Y-D, Ding, M, Dong, X, et al. Allergy. 2021; 76: 428– 455
Vaccines and allergic reactions: the past, the current COVID-19 pandemic, and future perspectives
Sampath, V., Rabinowitz, G., Shah, M., Jain, S., Diamant, Z., Jesenak, M. et al. Allergy. 2021; 76: 1640-1660
Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19
Azkur, A.,K., Akdis, M., Azkur, D., Sokolowska, M., van de Veen, W., Brüggen, M.,C. et al. Allergy. 2020; 75: 1564– 1581
EAACI guidelines: Anaphylaxis (2021 update)
Muraro, A, Worm, M, Alviani, C, et al. Allergy. 2022; 77: 357– 377
Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)
Bousquet, J., Khaltaev, N., Cruz, A.A., Denburg, J., Fokkens, W.J., Togias, A. et al. Allergy. 2008; 63: 8-160
Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China
Zhang, J.-J., Dong, X., Cao, Y.-Y., Yuan, Y.-D., Yan, Y.-Q., Akdis, C., A. and Gao, Y.-D. Allergy. 2020; 75: 1730– 1741
Advances and recent developments in asthma in 2020
Cevhertas, L, Ogulur, I, Maurer, DJ, et al. Allergy. 2020; 75: 3124– 3146
The international WAO/EAACI guideline for the management of hereditary angioedema – the 2021 revision and update
Maurer, M., Magerl, M., Betschel, S., et al. Allergy. First published: 10 January 2022
A compendium answering 150 questions on COVID-19 and SARS-CoV-2
Riggioni, C., Comberiati, P., Giovannini, M., Agache, I., Akdis, M., Alves-Correia, M. et al. Allergy. 2020; 75: 2503– 2541
Special Issue: Perspectives in Allergen Immunotherapy: 2019 and Beyond
Volume 74 | Issue S108
Management of anaphylaxis due to COVID-19 vaccines in the elderly
Bousquet, J., Agache, I., Blain, H., et al. Allergy. 2021; 76: 2952-2964
Predictors of treatment response in chronic spontaneous urticaria
Fok, J.S., Kolkhir, P., Church, M.K. and Maurer, M. Allergy. 2021; 76: 2965-2981
Interleukin-31: The “itchy” cytokine in inflammation and therapy
Datsi, A., Steinhoff, M., Ahmad, F., Alam, M. and Buddenkotte, J. Allergy. 2021; 76: 2982-2997
Markers for the involvement of endothelial cells and the coagulation system in chronic urticaria: A systematic review
Mostmans, Y., De Smedt, K., Richert, B., et al. Allergy. 2021; 76: 2998-3016
Eczema herpeticum in atopic dermatitis
Traidl, S., Roesner, L., Zeitvogel, J. and Werfel, T. Allergy. 2021; 76: 3017-3027
CytoBas: Precision component-resolved diagnostics for allergy using flow cytometric staining of basophils with recombinant allergen tetramers
McKenzie, C.I., Varese, N., Aui, P.M., et al. Allergy. 2021; 76: 3028-3040
Heterogeneity of pollen food allergy syndrome in seven Southern European countries: The @IT.2020 multicenter study
Lipp, T, Acar Şahin, A, Aggelidis, X, et al. Allergy. 2021; 76: 3041– 3052
Direct assessment of individual skin barrier components by electrical impedance spectroscopy
Mannweiler, R., Bergmann, S., Vidal-y-Sy, S., Brandner, J.M. and Günzel, D. Allergy. 2021; 76: 3094-3106
Prenatal paraben exposure and atopic dermatitis-related outcomes among children
Thürmann, L, Herberth, G, Seiwert, B, et al. Allergy. 2021; 76: 3122– 3132
Free human DNA attenuates the activity of antimicrobial peptides in atopic dermatitis
Kopfnagel, V, Dreyer, S, Zeitvogel, J, et al. Allergy. 2021; 76: 3145– 3154
Nanoarchitectures for efficient IgE cross-linking on effector cells to study amoxicillin allergy
Tesfaye, A., Rodríguez-Nogales, A., Benedé, S., et al. Allergy. 2021; 76: 3183-3193
Sweet syndrome induced by SARS-CoV-2 Pfizer-BioNTech mRNA vaccine
Darrigade, A.-S., Théophile, H., Sanchez-Pena, P., et al. Allergy. 2021; 76: 3194-3196
Transgenic mice overexpressing the PGE2 receptor EP2 on mast cells exhibit a protective phenotype in a model of allergic asthma
Urbano, A., Plaza, J., Turon, S., et al. Allergy. 2021; 76: 3196-3199
Type 2 biomarker expression (FeNO and blood eosinophils) is higher in severe adult-onset than in severe early-onset asthma
Lommatzsch, M., Klein, M., Stoll, P. and Virchow, J.C. Allergy. 2021; 76: 3199-3202
Identification of Ulocladium chartarum as an important indoor allergen source
Pfeiffer, S., Sandler, P., Raith, M., et al. Allergy. 2021; 76: 3202-3206
Effects of allergen immunotherapy in the MASK-air study: a proof-of-concept analysis
Pfaar, O., Sousa-Pinto, B., Devillier, P., et al. Allergy. 2021; 76: 3212-3214
Predicted number of peanut-allergic patients needed to treat with epicutaneous immunotherapy (EPIT) to prevent one allergic reaction: A novel approach to assessing relevance
Remington, B.C., Koppelman, S.J., Green, T.D., et al. Allergy. 2021; 76: 3223-3226
Legends of allergy and immunology: Sergio Bonini
Maltese, G. and Rasi, G. Allergy. 2021; 76: 3227-3229
Medical algorithm: Peri-operative management of mastocytosis patients
Bocca-Tjeertes, I.F.A., van de Ven, A.A.J.M., Koppelman, G.H., et al. Allergy. 2021; 76: 3233-3235
Open Access Agreements with Wiley
Check here if your research institution has an agreement with Wiley to make your Original Articles and Review Articles free to read, download and share by everyone: Institutional Payments | Wiley
18th World Immune Regulation Meeting
As ever, immune regulation is the hottest issue in basic and clinical sciences. With an outstanding list of speakers in this field, WIRM will be one of the key scientific event of the year 2024, being big enough to learn from other disciplines and small enough to personally meet the experts. Check out the website for more information by clicking here.
Junior Members Corner
Dear Junior Members,
The EAACI Congress was held in Hamburg, Germany, from 09-11 June 2023 under the motto Pathways from precision medicine to personalized health care in allergy and asthma, with more than 120 scientific sessions.
During the annual meeting, the Junior Member Assembly (JMA) worked intensively to promote the engagement of EAACI Junior Members (JMs) through different initiatives. From a scientific perspective, the JMA organised scientific sessions: Human inborn errors of immunity: An expanding universe, Is there a link between sports and respiratory diseases?, Effect of pollution and environmental stress in allergy, Immunomodulatory strategies, and the traditional JM case report session and JM poster session.
From an educational point of view, the JMA also organised the Initiatives symposium on the different activities and JM opportunities, with talks on the experience of JMs and seniors in different EAACI initiatives such as the mentorship and fellowship programs, and the Allergopharma award, followed by an educational cocktail. In addition, an educational symposium on how to maximise the impact of research was held.
During these days the JMA members also attended different meetings of EAACI Sections, Interest Groups, and Working Groups to discuss, participate, and coordinate different task forces and projects. Moreover, as one of the JMA's priorities is the collaboration with EAACI journals, we also held different meetings with the EAACI journals: Allergy, PAI and CTA.
The JMA also has several educational opportunities such as the Allergy College, where 14 undergraduate science and medical students were able to attend to the congress online or in person in Hamburg. In addition, during an online session, they were able to present their results in a friendly atmosphere with other JMs and senior scientists. Moreover, 3 EAACI JMs from all over the world received a scholarship to attend the EAACI Congress in person, thanks the new Tell Us About your Project, a program to promote the communication skills of JMs.
In summary, the congress has been a success, with a great participation of the EAACI JMs. From the JMA we would like to thank the intense participation of the JMs in all the activities organised during the congress, as well as the organizers and all EAACI members, who have made possible another total success of the Meeting.
Looking forward to seeing you again at the next congress in Valencia!
Best regards,
The Junior Member Assembly
EAACI Patients Organisation Committee Corner
You are invited to the EAACI Special Session! Let’s discuss “Benefits of engaging with patients in clinical trials and decision-making” at the EAACI Annual Congress 2023
The EAACI Patient Organisations Committee (POC), kindly invites you to the EAACI Special Session that will take place during the EAACI Congress 2023 in Hamburg on Friday 9 June 2023, 15:00-16:30 in Hall Y 01+02, the Congress Centre Hamburg CCH. Online attendance will also be available at Channel Y 01+02.
During the EAACI Special Session organised by POC, Giulia Gabrielli from European Medicine Agency will share the framework for engagement between the Agency and the patients. The European Medicines Agency (EMA) and patients have been actively interacting since the creation of the Agency in 1995. EMA states that patients bring a 'real-life' experience as well as specific knowledge and expertise to scientific discussions on medicines and on the impact of regulatory decisions.
Dr Kirsten Perrett, Director of Australia National Allergy Centre of Excellence, will be sharing their experience in receiving the federal funding for allergy prevention and management in collaboration with the patient organisation Allergy & Anaphylaxis Australia. She says “Together, we will implement the first national allergy registry alongside a live anaphylaxis reporting system, which will facilitate precision medicine and improve consumer safety and prevent anaphylaxis deaths.”
Regarding the civil society perspective, Susanna Palkonen, Director of European Federation of Allergy and Airways Diseases Patients Associations (EFA) will be sharing their long-lasting track record in participation to research projects. EFA believes synergies between patients and researchers are key to understanding, treating and preventing allergies and airways diseases.
In the recent years, the involvement of patients in research has been widely recognised as beneficial, helping to identify research priorities, reducing the withdrawal rate in clinical trials, and communicating scientific results. POC Member Mikaela Odemyr, President of Asthma- and Allergyassociation will be sharing their experience in Sweden.
The session chairs will be Carla Jones, CEO of Allergy UK, past POC Co-Chair and Ozlem Ceylan, President of Living with Allergy Association, current POC Chair. The session will also have a panel discussion where chairs will invite the audience to share their experiences or best practises.
POC is looking forward to seeing you in Hamburg or online!
The EAACI Patient Organisations Committee (POC), kindly invites you to the EAACI Special Session that will take place during the EAACI Congress 2023 in Hamburg on Friday 9 June 2023, 15:00-16:30 in Hall Y 01+02, the Congress Centre Hamburg CCH. Online attendance will also be available at Channel Y 01+02.
During the EAACI Special Session organised by POC, Giulia Gabrielli from European Medicine Agency will share the framework for engagement between the Agency and the patients. The European Medicines Agency (EMA) and patients have been actively interacting since the creation of the Agency in 1995. EMA states that patients bring a 'real-life' experience as well as specific knowledge and expertise to scientific discussions on medicines and on the impact of regulatory decisions.
Dr Kirsten Perrett, Director of Australia National Allergy Centre of Excellence, will be sharing their experience in receiving the federal funding for allergy prevention and management in collaboration with the patient organisation Allergy & Anaphylaxis Australia. She says “Together, we will implement the first national allergy registry alongside a live anaphylaxis reporting system, which will facilitate precision medicine and improve consumer safety and prevent anaphylaxis deaths.”
Regarding the civil society perspective, Susanna Palkonen, Director of European Federation of Allergy and Airways Diseases Patients Associations (EFA) will be sharing their long-lasting track record in participation to research projects. EFA believes synergies between patients and researchers are key to understanding, treating and preventing allergies and airways diseases.
In the recent years, the involvement of patients in research has been widely recognised as beneficial, helping to identify research priorities, reducing the withdrawal rate in clinical trials, and communicating scientific results. POC Member Mikaela Odemyr, President of Asthma- and Allergyassociation will be sharing their experience in Sweden.
The session chairs will be Carla Jones, CEO of Allergy UK, past POC Co-Chair and Ozlem Ceylan, President of Living with Allergy Association, current POC Chair. The session will also have a panel discussion where chairs will invite the audience to share their experiences or best practises.
POC is looking forward to seeing you in Hamburg or online!
